CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

203923Orig1s000

CHEMISTRY REVIEW(S)
Memorandum

To: NDA 203-923

Subject: To amend the NDA with the updated product expiry of 18 months.

From: Xiaobin Shen, Ph.D., Reviewer, Branch VIII, Division III, ONDQA.

NDA 203-923 referenced to NDA 201-444 for support of CMC information.

Supplement-003 of NDA 201-444 has been reviewed and an expiry of 18 month is granted for the sodium thiosulfate product.

Hence, this memorandum updates the expiry of sodium thiosulfate in NDA 203-923 from the previously granted 14 months.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

XIAOBIN SHEN
02/14/2012
Updating the product expiry.

ERIC P DUFFY
02/14/2012

Reference ID: 3087564
NDA 203-923

Sodium Thiosulfate, 250 mg/mL

Hope Pharmaceuticals

Xiaobin Shen, Ph.D.
Division of Anesthesia, Analgesia and Addiction Drug Products
# Table of Contents

Table of Contents ........................................................................................................... 2

Chemistry Review Data Sheet .......................................................................................... 3

The Executive Summary .................................................................................................. 7

I. Recommendations ........................................................................................................ 7
   A. Recommendation and Conclusion on Approvability .................................................. 7
   B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable .................................................. 7

II. Summary of Chemistry Assessments ........................................................................... 8
   All CMC information is referenced to NDA 201-444. Only brief information is provided below. ................................................................. 8
   A. Description of the Drug Substance and Drug Product ............................................. 8
   B. Description of How the Drug Product is Intended to be Used ............................... 8
   C. Basis for Approvability or Not-Approval Recommendation .................................. 9

III. Administrative ............................................................................................................ 9
   A. Reviewer’s Signature ............................................................................................... 9
   B. Endorsement Block ............................................................................................... 9
   C. CC Block ................................................................................................................ 9

Chemistry Assessment ...................................................................................................... 10

I. Review Of Common Technical Document-Quality (Ctd-Q) Module 3.2: Body of Data ................................................................. 10

II. Review Of Common Technical Document-Quality (Ctd-Q) Module 1 ...................... 10
   A. Labeling ................................................................................................................ 10
   B. Package Insert ....................................................................................................... 11
   B. Environmental Assessment Or Claim Of Categorical Exclusion .......................... 12
Chemistry Review Data Sheet

1. NDA 203-923

2. REVIEW #: 1

3. REVIEW DATE: 31-Jan-2012

4. REVIEWER: Xiaobin Shen, Ph.D.

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>03-Jan-2012</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

   Name: Hope Pharmaceuticals
   Address: 16416 N. 92nd Street #125
             Scottsdale, AZ 85260
   Representative: Craig Sherman, M.D.
   Telephone: 480-607-1970

8. DRUG PRODUCT NAME/CODE/TYPE:

   a) Proprietary Name: Sodium Nitrite Injection, USP
   b) Non-Proprietary Name (USAN): Sodium Nitrite
c) Code Name/# (ONDC only): N/A


d) Chem. Type/Submission Priority (ONDC only):
   • Chem. Type: 1S
   • Submission Priority: P

9. LEGAL BASIS FOR SUBMISSION: NDA 505(b)(2)

10. PHARMACOL. CATEGORY: Antidote

11. DOSAGE FORM: IV Injection

12. STRENGTH/POTENCY: Sodium Thiosulfate

13. ROUTE OF ADMINISTRATION: Intravenous

14. Rx/OTC DISPENSED:  X  Rx  OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
   _____SPOTS product – Form Completed
   X  Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

   Sodium Thiosulfate
   Chemical name: Sodium thiosulfate pentahydrate
   United States Adopted Name (USAN): Sodium thiosulfate
   Compendial name: Sodium thiosulfate pentahydrate, United States Pharmacopeia (USP)
   Chemical structure:

   \[
   \text{Na}^+ \overset{\text{S}}{\underset{\text{O}}{\text{S}}} \overset{\text{O}^-}{\underset{\text{Na}^+}{\text{S}}} \cdot 5\text{H}_2\text{O}
   \]

   Molecular formula: \( \text{Na}_2\text{O}_3\text{S}_2\cdot5\text{H}_2\text{O} \)
   Molecular weight: 248.19 g/mol
Sodium thiosulfate anhydrous has a molecular formula of Na₂O₃S₂ and has a molecular weight of 158.11 g/mol.

17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE¹</th>
<th>STATUS²</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>III</td>
<td></td>
<td></td>
<td>3*</td>
<td>Adequate</td>
<td>14-Oct-2008</td>
<td>Reviewed by Dr. Donald Klein</td>
</tr>
<tr>
<td></td>
<td>V</td>
<td></td>
<td></td>
<td>7</td>
<td>Adequate</td>
<td>05-Jan-2009</td>
<td>Reviewed by Dr. Steven Donald</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td></td>
<td></td>
<td>7</td>
<td>Adequate</td>
<td>NA</td>
<td>meets safety requirement per MAPP</td>
</tr>
</tbody>
</table>

* The stopper used in this NDA is reviewed previously and deemed adequate to support various injection products. The most recent review was performed by Dr. Donald Klein on 14-Oct-2008. The stopper reviewed by Dr. Mark Sassaman on 12-Apr-2007 and deemed adequate. The DMF was reorganized and resubmitted on 08-May-2009 with information related to other coating materials.

¹ Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under "Comments")

² Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)

B. Other Documents:

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>
18. STATUS:

**ONDC:**

<table>
<thead>
<tr>
<th>CONSULTS/ CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>All are referenced to the already approved NDA 201-444, no further assessment is required. See details in the Executive Summary.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biopharm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LNC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methods Validation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMEPA/OSE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microbiology</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The Chemistry Review for NDA 203-923

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

From the chemistry, manufacturing and controls standpoint, the NDA is recommended for approval.

This NDA is submitted for the purpose of having individually packaged sodium thiosulfate component of the Nithiodote drug product already approved in NDA 201-444. There is no further change beyond those related to package insert, packaging carton and carton labeling.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

Not applicable for this NDA. All relevant information is referenced to NDA 201-444.

At the time of approval for NDA 201-444, the following Post Marketing Requirements (1 & 2) and Post Marketing Commitments (3 & 4) were established —

1. Hope will provide the levels of [redacted] leachables testing (ideally from multiple batches) of an Agency-approved parenteral product(s) packaged in Type I USP [redacted] vial.

2. Hope will report the results of an extractable study that individually investigates the rubber stopper and Type I USP [redacted] vial using both drug product solutions (in independent experiments) as the extraction medium.

3. Hope will conduct pharmaceutical development studies to explore —
   a. Alternative container closure systems that may include alternative rubber stoppers [redacted] different glass vial sources, and [redacted] bottles.
   b. Alternative methods of [redacted] sterilization [redacted] may be investigated. Any manufacturing changes will be validated in context of the expected microbial load.

4. Hope will amend the post-approval stability protocol to include leachable monitoring in the two drug products. The protocol will include monitoring at release, 3, and 6 months under accelerated stability conditions and monitoring at release, 6, 12, 24, 36, 48 and 60 months under real time storage conditions for the post-approval stability batches (at least the first three commercial batches).

Items 1 and 2 (PMRs) were satisfied on 22-Mar-2011, for details refer to the CMC Memo to File conducted by Dr. Olen Stephens on 30-Mar-2011.
Item 4 (PMC) were satisfied on 23-Feb-2011, for details refer to the CMC Memo to File conducted by Dr. Olen Stephens on 01-Mar-2011.

Hence, for the referenced NDA 201-444, only one PMC (Item 3) is outstanding.

II. Summary of Chemistry Assessments

All CMC information is referenced to NDA 201-444. Only brief information is provided below. cGMP status of all facilities are acceptable.

A. Description of the Drug Substance and Drug Product

The sodium thiosulfate drug substance is prepared Starting materials are commercially available. Specifications for the starting materials, reagents, in-process control, and final drug substance quality control are adequate. Sufficient stability data is provided to grant a retest date for the sodium thiosulfate drug substance.

NDA 203-923 is submitted as a 505(b)(2), based on the approved NDA 201-444, NITHIODOTE® injection. The sodium thiosulfate injection product is indicated for, and used in combination with sodium nitrite injection, the treatment of acute cyanide poisoning that is judged to be life-threatening. The sodium thiosulfate injection product is individually packaged, in contrast to that co-packaged with sodium nitrite in NDA 201-444. The package insert and carton labeling are modified to reflect this package configuration.

The sodium thiosulfate drug product is formulated as a solution followed by . The sodium thiosulfate drug product is buffered with boric acid/sodium hydroxide and adjusted for tonicity by potassium chloride. The drug product is filled into USP Type 1 glass vials and stoppered and a aluminum overseal. The vials are packaged in a box, the secondary container. Release and stability testing include testing for bacterial endotoxins, sterility, and container integrity testing. Photostability, thermostability, oxygen stress, and temperature cycling studies showed the drug product as insensitive to these stability stressors. Sufficient stability data is provided to allow a month shelf life.

B. Description of How the Drug Product is Intended to be Used

The following dosing regimen is proposed. Sodium nitrite is administered first followed immediately by sodium thiosulfate. The same needle and vein may be used to administer both solutions.

Adults:

Sodium Nitrite: 10 mL of a 3% solution (300 mg) of sodium nitrite at the rate of 2.5 to 5 mL/minute.
CHEMISTRY REVIEW

Executive Summary Section

Sodium Thiosulfate: 12.5 g (50 mL of a 25% solution) immediately following administration of sodium nitrite.

Redosing: If a patient does not respond to initial doses, treatment may be repeated with one-half the original dose of sodium nitrite followed by one-half the original dose of sodium thiosulfate.

Children:
Sodium Nitrite: 0.2 mL/kg of a 3% solution (6 mg/kg or 6-8 mL/m² BSA) of sodium nitrite at the rate of 2.5 to 5 mL/minute not to exceed 10 mL (300 mg).
Sodium Thiosulfate: 1 mL/kg of body weight using a 25% solution (250 mg/kg or approximately 30-40 mL/m² of BSA) not to exceed 50 mL (12.5 g) total dose.

Storage and Expiry:
Store between 20°C and 25°C (68°F - 77°F); excursions permitted to 15 - 30°C (59°F - 86°F). Protect from direct light and keep the vials in their secondary container. Do not permit the drug products to freeze. The product expiry is 48 months, as determined in the supplement review conducted by Dr. Pramoda Maturu on 28-Sep-2011. Supplement S003 for NDA 201-444 requested an expiry of 24 months, it is currently under review, the expiry determined applies to this NDA.

C. Basis for Approvability or Not-Approval Recommendation
This new NDA for the sodium thiosulfate individual component of the kit, sodium nitrite and sodium thiosulfate injection, is referenced to the already approved NDA 201-444 for support of approval. There are no updates to the CMC portion of the application(s), except for the update of labeling for the individual components, which have to be administered sequentially for this indication.

III. Administrative

A. Reviewer’s Signature

Review is digitally signed off in DARRTS.

B. Endorsement Block

ChemistName/Date: Same date as draft review
ChemistryTeamLeaderName/Date
ProjectManagerName/Date

C. CC Block

7 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

XIAOBIN SHEN
01/31/2012
The NDA is recommended for approval from CMC perspective.

PRASAD PERI
01/31/2012
I concur